Menu Search
Equities

Medios AG

ILM1:HAM

Medios AG

Actions
  • Price (EUR)13.04
  • Today's Change-0.68 / -4.96%
  • Shares traded160.00
  • 1 Year change-23.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medios AG, formerly Crevalis Capital AG, is a Germany-based company that is active in the pharmacy business. It wholesales, markets, distributes and produces various kinds of goods for pharmacies and other pharmaceutical companies. The Company also provides related services and is engaged in the acquisition and management of other companies from the pharmaceutical industry.

  • Revenue in EUR (TTM)1.84bn
  • Net income in EUR12.88m
  • Incorporated1999
  • Employees1.00k
  • Location
    Medios AGHeidestrasse 9BERLIN 10557GermanyDEU
  • Phone+49 30 232566800
  • Fax+49 30 232566801
  • Websitehttps://medios.ag/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ILM1X:GER since
announced		Transaction
value
Ceban Pharmaceuticals BVAnnounced19 Mar 202419 Mar 2024Announced-5.04%282.65m
Data delayed at least 15 minutes, as of Nov 22 2024 14:37 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.